Daniel L. Kaufman
25Patents
9h-index
9Co-inventors
68Inventor score
Filing activity: Sep 21, 1990 → Mar 22, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5846740A | Methods and kits useful for detecting autoantibody to glutamic acid decarboxylase | Emerging Cross-Sectional Technologies | 51 | Expired |
| US5998366A | Method for ameliorating glutamic acid decarboxylase associated autoimmune disorders | Physics | 44 | Expired |
| US5674978A | Peptides derived from glutamic acid decarboxylase | Emerging Cross-Sectional Technologies | 41 | Expired |
| US5475086A | Cloned glutamic acid decarboxylase peptides | Physics | 39 | Expired |
| US6455267B1 | Methods and kits useful for determining the status of and detecting pancreatic B-cell associated autoimmune diseases | Emerging Cross-Sectional Technologies | 35 | Expired |
| US6011139A | Hybridomas and monoclonal antibodies that specifically bind to glutamic acid decarboxylase peptides | Emerging Cross-Sectional Technologies | 34 | Expired |
| US5705626A | Cloned glutamic acid decarboxylase nucleic acids | Physics | 34 | Expired |
| US6682906B1 | Cloned glutamic acid decarboxylase | Physics | 32 | Expired |
| US6277586A | Cloned glutamic acid decarboxylase | Physics | 31 | Expired |
| US6207159A | Methods for the diagnosis and treatment of insulin-dependent diabetes mellitus | Emerging Cross-Sectional Technologies | 9 | Expired |
| US6350769B1 | Gaba alpha receptors mediate inhibition of T cell responses | Human Necessities | 9 | Expired |
| US9089531B2 | GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes | Human Necessities | 7 | Active |
| US7282563B2 | Opioid receptors and methods of use | Human Necessities | 6 | Expired |
| US9820955B2 | GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes | Human Necessities | 5 | Active |
| US6022697A | Methods for the diagnosis and treatment of insulin-dependent diabetes mellitus | Emerging Cross-Sectional Technologies | 4 | Expired |
| US6432652B1 | Methods of screening modulators of opioid receptor activity | Chemistry; Metallurgy | 2 | Expired |
| US10434078B2 | GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes | Human Necessities | 2 | Active |
| US7553484B2 | Modulating neuronal outgrowth via the major histocompatibility complex class I (MHC I) molecule | Chemistry; Metallurgy | 1 | Expired |
| US6265563A | Opioid receptor genes | Human Necessities | 1 | Expired |
| US11872200B2 | GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes | Human Necessities | 0 | Active |
| US7329511B2 | Nucleic acid encoding GAD65 | Physics | 0 | Expired |
| US10952980B2 | GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes | Human Necessities | 0 | Active |
| US8926966B1 | Cloned glutamic acid decarboxylase | Emerging Cross-Sectional Technologies | 0 | Expired |
| US7723071B2 | DNA molecules encoding opioid receptors and methods of use thereof | Human Necessities | 0 | Active |
| US11992495B2 | Enhancing GABA's ability to modulate immune responses | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.